Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amylyx Pharmaceuticals, Inc. (AMLX)

36.08   -0.92 (-2.49%) 02-03 14:15
Open: 36.67 Pre. Close: 37
High: 37.38 Low: 36.02
Volume: 320,590 Market Cap: 2,391(M)

Technical analysis

as of: 2023-02-03 1:44:36 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 44.86     One year: 48.96
Support: Support1: 32.74    Support2: 27.24
Resistance: Resistance1: 38.41    Resistance2: 41.91
Pivot: 38.34
Moving Average: MA(5): 38.58     MA(20): 37.86
MA(100): 35.11     MA(250): 25.26
MACD: MACD(12,26): 0.5     Signal(9): 0.7
Stochastic oscillator: %K(14,3): 52.9     %D(3): 64.4
RSI: RSI(14): 44.9
52-week: High: 41.91  Low: 6.51
Average Vol(K): 3-Month: 785 (K)  10-Days: 783 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMLX ] has closed above bottom band by 25.2%. Bollinger Bands are 14.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 40.93 - 41.13 41.13 - 41.32
Low: 35.16 - 35.39 35.39 - 35.61
Close: 36.57 - 36.94 36.94 - 37.3

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 02 Feb 2023
2023-02-02 | NDAQ:AMLX | Press Release | Amylyx ... - Stockhouse

Mon, 30 Jan 2023
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average ... - MarketBeat

Wed, 25 Jan 2023
With 40% ownership in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), institutional investors have a lot riding on the business - Simply Wall St

Wed, 25 Jan 2023
Kestra Advisory Services LLC Invests $1.20 Million in Amylyx ... - MarketBeat

Thu, 19 Jan 2023
Can Amylyx Pharmaceuticals Inc (AMLX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver

Tue, 17 Jan 2023
Amylyx Pharmaceuticals Announces Exclusive AMX0035 ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 3.083e+007 (%)
% Held by Institutions 24.9 (%)
Shares Short 3,680 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.5313e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -53
Return on Assets (ttm) 789.4
Return on Equity (ttm) 0
Qtrly Rev. Growth 285000
Gross Profit (p.s.) -0.43
Sales Per Share 0.01
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -136 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales 3237.9
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 6.7e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.